Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization February 5, 2025
FDA Approval of Eli Lilly’s Omvoh for Crohn’s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists’ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights January 31, 2025
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights January 9, 2025